Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

First phase II results presented for LY-3298176 in patients with type 2 diabetes

Oct. 8, 2018

Hepato-preferential insulin analogue protects dogs from hypoglycemia

Oct. 8, 2018

KINGS mouse as a novel preclinical model of diabetes

Oct. 8, 2018

Alnylam reports phase I/II data on lumasiran in PH1, initiates phase III trial

Oct. 5, 2018

Encouraging initial data presented from two ongoing studies of Trappsol Cyclo in NPC

Oct. 4, 2018

Researchers identify Lrrc55 as potential new target in pancreatic beta cells

Oct. 4, 2018

CD44 as novel therapeutic target in diabetes

Oct. 4, 2018

CXCL14 downregulation as novel therapeutic strategy in type 2 diabetes

Oct. 4, 2018

Knockout of HRD1 protects mice from high fat diet-induced obesity

Oct. 4, 2018

Series A financing to support Modis' development of MT-1621 for thymidine kinase 2 deficiency

Oct. 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 29, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Chinese biotechs gain leverage as partners in dealmaking
BioWorld
China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
Roche identifies new TREM2 agonists
BioWorld Science
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
Plasticity, properly parsed, provides psychiatric platform
BioWorld
If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...